Clinical Study

Streptococcal Pharyngitis: A Prospective Study of Compliance and Complications

Table 1

Patient demographic characteristics in subgroups; age, medical-associated illnesses, and antibiotics prescribed at initial presentation. (% in parenthesis).

Length of treatment in subgroupNo treatment 𝑛 = 2 1 3 (11)1 to 3 days 𝑛 = 9 7 9 (49)4 to 6 days 𝑛 = 6 1 2 (30)7 to 10 days 𝑛 = 1 9 6 (10) 𝑃 value

Mean age of patient enrolled

Mean Age9.2101111 .04

Patient demographic by group

Age 0.5 to 5.9 years 𝑛 = 1 0 2 3 (51)137 (13)469 (46)326 (32)91 (9)<.0001
Age 6 to 9.9 years 𝑛 = 4 9 9 (25)36 (7.5)245 (49)145 (29)73 (14.5)<.0001
Age 10 to 13.9 years 𝑛 = 3 7 8 (19)40 (10)195 (52)116 (31)27 (7)<.0001
Age 14 to 18 years 𝑛 = 1 0 0 (5)070 (70)25 (25)5 (5)<.0001

Febrile days

1 or less days of fever 𝑛 = 1 7 1 6 (85)175 (10)881 (51.5)470 (27.5)190 (11)<.0001
1 to 3 days of fever 𝑛 = 1 6 4 (9)35 (21)27 (17)97 (59)5 (3)<.0001
4 to 6 days of fever 𝑛 = 1 2 0 (6)3 (2.5)71 (59)45 (37.5)1 (1)<.0001

Medically associated illnesses

Conjunctivitis
𝑛 = 3 6 (1.5)
5 (14)8 (22)9 (25)14 (39)<.0001
Otitis media
𝑛 = 3 9 (1.5)
3 (8)9 (23)15 (38)12 (31)<.0001
URI
𝑛 = 7 4 (4)
7 (10)34 (46)23 (31)23 (13)<.0001
Gastroenteritis
𝑛 = 2 5 (1)
8 (32)12 (48)5 (20)0<.0001
Lymphadenitis
𝑛 = 1 8 3 1 (92)
167 (9)925 (51)553 (30)186 (10)<.0001

Antibiotics prescribed

Penicillin
𝑛 = 1 2 1 0 (60.5)
60 (5)533 (44)476 (39)141 (12)<.0001
Amoxicillin
𝑛 = 6 1 1 (30)
105 (17)361 (59)111 (18)34 (6)<.0001
Azithromycin
𝑛 = 1 0 9 (5.5)
37 (34)52 (48)20 (18)0<.0001
Cephalosporin = cefovit 𝑛 = 2 5 (1.5)7 (28)17 (68)01 (4)<.0001
Erythromycin
𝑛 = 4 5 (2.5)
4 (9)16 (36)5 (11)20 (44)<.0001